Author:
Saha Bibek,Verma Anjul,Iyer Prasad G.
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, et al. Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline. Official journal of the American College of Gastroenterology | ACG. 2022;117:559–87.
2. Saha B, Vantanasiri K, Mohan BP, Goyal R, Garg N, Gerberi D, et al. Prevalence of Barrett’s Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;S1542–3565(23):00848. A systematic review and meta-analysis highlighting that BE prevalence in those without GERD is substantial at 4.9% in large population-based studies.
3. Nguyen TH, Thrift AP, Rugge M, El-Serag HB. Prevalence of Barrett’s esophagus and performance of societal screening guidelines in an unreferred primary care population of U.S. veterans. Gastrointestinal Endoscopy. 2021;93:409–419.e1. A retrospective analysis of a prospective cross-sectional study that demonstrated that ACG, ASGE, ESGE, and BSG guidelines, which all have the presence of GERD as the primary criterion for screening, have low sensitivities and only modest specificities for BE screening. In contrast, AGA guidelines that do not require GERD, was found to have a low specificity for BE screening.
4. Coleman HG, Xie S-H, Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology. 2018;154:390–405.
5. Taylor JB, Rubenstein JH. Meta-Analyses of the Effect of Symptoms of Gastroesophageal Reflux on the Risk of Barrett’s Esophagus. Am J Gastroenterol. 2010;105:1730–7.